Teriparatide Injection, Solution
NDC Package 66993-989-28
Package Information
Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. This formulation utilizes a injection, solution delivery system. Marketed by Prasco Laboratories, this product is identified by NDC 66993-989 and is authorized under FDA application NDA021318.
Identification & Billing
- RxCUI: 1435115 - teriparatide 20 MCG/Dose in 28 Dose Pen Injector
- RxCUI: 1435115 - 28 ACTUAT teriparatide 0.02 MG/ACTUAT Pen Injector
- RxCUI: 1435115 - teriparatide 0.02 MG/ACTUAT Pen Injector, 28 ACTUAT
- RxCUI: 1435115 - teriparatide 20 MCG/ACTUAT Pen Injector, 28 ACTUAT
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 66993 - Prasco Laboratories
- 66993-989 - Teriparatide
- 66993-989-28 - 1 SYRINGE in 1 CARTON / 2.24 mL in 1 SYRINGE
- 66993-989 - Teriparatide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 66993-989-28 identifies a specific commercial package of 1 syringe in 1 carton / 2.24 ml in 1 syringe of Teriparatide, a human prescription drug labeled by Prasco Laboratories. This injection, solution is formulated for subcutaneous use and contains teriparatide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Prasco Laboratories on June 16, 2025. The current certification is valid through December 31, 2026.
How is this Prasco Laboratories product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 66993098928. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 2.24 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.